利妥昔单抗、吉西他滨与奥沙利铂治疗复发/难治性惰性与套细胞淋巴瘤：德国低度恶性淋巴瘤研究组多中心 I/II 期研究结果

Rituximab, gemcitabine and oxaliplatin (R-GemOx) has demonstrated to be effective and safe in lymphoma patients.

We aimed to determine the maximum tolerated dose (MTD) of oxaliplatin in combination with rituximab and gemcitabine and to explore the efficacy and safety of R-GemOx in relapsed or refractory (r/r) indolent and mantle cell lymphoma (MCL). In this single-arm, phase I/II trial, we enrolled 55 patients with r/r indolent lymphoma and MCL not suitable for autologous stem-cell transplantation. Patients received 4 cycles of R-GemOx. In the dose escalation group, 70 mg/m 2 of oxaliplatin was applied and interindividually increased by 10 mg/m 2 until the MTD was reached together with fixed doses of rituximab and gemcitabine. At the oxaliplatin MTD, an extension cohort was opened.

Primary aim was to detect an overall response rate (ORR) greater than 65% ( = 0. 05). Oxaliplatin 70 mg/m 2 (MTD) was chosen for the extension cohort after 3 of 6 patients experienced a DLT at 80 mg/m 2 . Among 46 patients evaluable for the efficacy analysis ORR was 72% (33/46), missing the primary aim of the study (p = 0. 21). After a median follow-up of 7.

9 years, median PFS and OS were 1. 0 and 2. 1 years. Most frequent grade 3 adverse events were cytopenias. R-GemOx induces decent response rates in r/r indolent lymphoma and MCL, though novel targeted therapies have largely replaced chemotherapy in the relapse setting. Particularly in MCL, R-GemOx might be an alternative option in late relapses or as bridging to CAR-T-cells.

This study was registered with ClinicalTrials. gov on Aug 4th, 2009, number NCT00954005.